Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Publication of AR099899A1publicationCriticalpatent/AR099899A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente se refiere a anticuerpos y fragmentos que se unan a un supresor del dominio V de lg para activación de linfocitos T (VISTA), y a métodos para utilizar los mismos. Los métodos de uso incluyen métodos para el tratamiento del cáncer, incluyendo leucemias, linfomas, tumores sólidos y melanomas. Reivindicación 1: Un anticuerpo aislado o fragmento de anticuerpo del mismo que comprende una región de unión a antígeno que se une a un supresor del dominio V de Ig para activación de linfocitos T (VISTA), donde la unión del anticuerpo o fragmento de anticuerpo a VISTA modula o potencia una respuesta inmune.This refers to antibodies and fragments that bind to a suppressor of the V domain of lg for T lymphocyte activation (VISTA), and methods for using them. The methods of use include methods for the treatment of cancer, including leukemia, lymphomas, solid tumors and melanomas. Claim 1: An isolated antibody or antibody fragment thereof comprising an antigen binding region that binds to an Ig V domain suppressor for T lymphocyte activation (VISTA), wherein the antibody or antibody fragment binding to VISTA modulates or enhances an immune response.
ARP150100962A2014-11-262015-03-30
ANTI-VISTA ANTIBODIES AND FRAGMENTS
AR099899A1
(en)
ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER